1-cyclohexylmethyl-5-[2-(2,3-dihydrobenzofuran-5-yl)thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide | 726179-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 1-cyclohexylmethyl-5-[2-(2,3-dihydrobenzofuran-5-yl)thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide
• 英文别名: cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide；N-butyl-1-(cyclohexylmethyl)-5-[2-(2,3-dihydro-1-benzofuran-5-yl)-1,3-thiazol-4-yl]-2-methylpyrrole-3-carboxamide
• CAS: 726179-69-7
• 化学式: C₂₈H₃₅N₃O₂S
• 分子量: 477.671
• InChiKey: FOGIUWDFIBMIFG-UHFFFAOYSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel pyrrolyl-thiazole derivatives
  申请人：——

  公开号：US20040147572A1

  公开（公告）日：2004-07-29

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及公式(I)1中的化合物，其中R1、R2、R3、R4、R5、R6和R7如描述和索赔中定义，并其药用盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。
• PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1583762A1

  公开（公告）日：2005-10-12
• US7135488B2
  申请人：——

  公开号：US7135488B2

  公开（公告）日：2006-11-14
• [EN] NOVEL CB 1 RECEPTOR INVERSE AGONISTS<br/>[FR] PYRROLYL-THIAZOLES ET LEUR UTILISATION EN TANT QU'AGONISTES INVERSES DU RECEPTEUR CB 1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004060888A1

  公开（公告）日：2004-07-22

  The present invention relates to compounds of formula (1) wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CBI receptors.